Nav: Home

Buprenorphine cuts length of stay nearly in half for infants withdrawing from opioids

May 04, 2017

PHILADELPHIA -- Babies born to women who have used opioids at any point during pregnancy are at risk of suffering withdrawal symptoms - collectively called neonatal abstinence syndrome (NAS) - that can cause serious problems in the infant. To reduce the severity of these symptoms, infants are treated with opioids and then slowly weaned off over the course of about a month, requiring a prolonged hospital stay. New research published May 4 in the New England Journal of Medicine demonstrated that a more effective treatment can safely cut the duration of therapy nearly in half.

"This is a practice-changing advance for treatment of babies with NAS," says the lead author of the study Walter Kraft, M.D., Professor and Director, Clinical Research Unit in the Department of Pharmacology and Experimental Therapeutics in the Sidney Kimmel Medical College at Thomas Jefferson University. "We predict that buprenorphine will become the new standard of care for NAS."

The current standard of care for infants who experience withdrawal symptoms, or NAS, is treatment with morphine until the symptoms subside. However, because pediatric populations are difficult to study, robust evidence from clinical trials supporting morphine were lacking.

"Testing therapeutics in infants has always been challenging. Families are understandably apprehensive about entering their infants into clinical trials," says Kraft. "But it is essential that we study whether these therapies are effective, because infants are not simply smaller versions of adults. Their physiology is unique and we need to continue to build evidence for their treatment. Improving care based on solid evidence was at the heart of this study."

The clinical trial was designed with multiple checks and balances to ensure the results were not skewed by the perception of the families or the health care providers. Between October 2011 and May 2016, the investigators enrolled 63 infants in the study and divided them into two treatment groups. Infants with withdrawal symptoms were treated with either morphine or buprenorphine in a blinded fashion so that neither the health care providers nor the families knew which treatment was given after all of the data was collected.

The research team found that the 30 infants treated with morphine required the therapy for an average of 28 days before their withdrawal symptoms were under control and they were fully weaned. Whereas the 33 infants allocated to buprenorphine only required an average of 15 days of the medication. The buprenorphine reduced treatment time by 47 percent.

"We suspect that buprenorphine is more effective because it works a little differently at the opioid receptor. It is also a longer lasting drug than morphine, requiring a dose every eight hours rather than the four required for morphine," says Kraft. The trial found buprenorphine to be as safe as morphine. Though not tested in this study, treatment of infants at home with buprenorphine may eventually be possible due to these favorable characteristics.

"The beauty of our results is that the drug is immediately readily available, unequivocally effective, non-invasive and safe. This could impact standard of care for and the financial cost of neonatal abstinence syndrome," said Michelle E. Ehrlich, M.D., from The Icahn School of Medicine at Mount Sinai, who had initiated research on buprenorphine at Jefferson with Dr. Kraft before moving to New York. "In future studies, Dr. Kraft and I hope to research how genetics may inform and influence an infant's response to medication."

Many mothers with substance abuse history who enrolled their infants in the study were treated with counseling, medication and group therapy at the Maternal Addiction Treatment Education and Research (MATER) program at Jefferson led by co-author Diane Abatemarco, Ph.D. This nationally-recognized program recently received a Center of Excellence grant from the State of Pennsylvania's Department of Human Services to strengthen care coordination.

"Jefferson has led the charge on treating neonatal abstinence syndrome since the 1970s," says Dr. Kraft. "Research within this population is challenging and the strength of the results speaks to the clinical staff who worked with the families and helped them feel fully supported by our team, in a way that was non-judgmental. This partnership was essential to finding such meaningful results."
-end-
Authors who contributed to this study include:

Susan C. Adeniyi-Jones, M.D., and Jay S. Greenspan, M.D., hold joint appointments at the Sidney Kimmel Medical College of Thomas Jefferson University, and Nemours/Alfred I. duPont Hospital for Children; Inna Chervoneva, Ph.D., Diane Abatemarco, Ph.D., and Karol Kaltenbach Ph.D., are with the Sidney Kimmel Medical College at Thomas Jefferson University; and Michelle E. Ehrlich M.D. is with The Icahn School of Medicine at Mount Sinai.

Article reference: W.K. Kraft, et al., "Buprenorphine for the treatment of the neonatal abstinence syndrome," New England Journal of Medicine, DOI: 10.1056/NEJMoa1614835. 2017.

The study was funded by National Institute on Drug Abuse (R01DA02976). Indivior supplied buprenorphine, but was not involved in the study design; data collection, analysis, or interpretation; or manuscript preparation. The authors report no other conflicts of interest.

About Jefferson
Jefferson, through its academic and clinical entities of Thomas Jefferson University and Jefferson Health, including Abington Health and Aria Health, is reimagining health care for the greater Philadelphia region and southern New Jersey. Jefferson has 23,000 people dedicated to providing the highest-quality, compassionate clinical care for patients, educating the health professionals of tomorrow, and discovering new treatments and therapies to define the future of care. With a university and hospital that date back to 1824, today Jefferson is comprised of six colleges, nine hospitals, 34 outpatient and urgent care locations, and a multitude of physician practices throughout the region, serving more than 100,000 inpatients, 373,000 emergency patients and 2.2 million outpatients annually.

Thomas Jefferson University

Related Clinical Trials Articles:

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.
Telemedicine helps improve participation in clinical trials
Videos and creative uses of other visuals provide a novel way to obtain informed consent during clinical trials to improve participants' understanding and retention of trial information, according to a study by Nemours Children's Health System presented at the American Thoracic Society (ATS) Annual Conference.
Not enough women included in some heart disease clinical trials
Women are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome but proportionately or overrepresented in trials for hypertension, atrial fibrillation and pulmonary arterial hypertension, when compared to incidence or prevalence of women within each disease population, according to a study in the Journal of the American College of Cardiology.
BU: Obese patients underrepresented in cancer clinical trials
A new review by Boston University School of Public Health researchers found that less than one-fifth of participants in cancer-related clinical trials are obese.
Are women really under-represented in clinical trials?
Several studies have reported a lack of gender diversity in clinical trials, with trials including mostly adult males; however, a recent review of publicly available registration data of clinical trials at the US Food and Drug Administration for the most frequently prescribed drug classes found no evidence of any systemic significant under-representation of women.
More Clinical Trials News and Clinical Trials Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.